文献速递浆细胞疾病造血干细胞移植与细胞治疗

一种新型BCMA/CD3双特异性T细胞衔接器治疗多发性骨髓瘤在体外和体内诱导选择性裂解

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
PubMed 文献 · Leukemia · 2016-12-27

研究开发了靶向BCMA和CD3ɛ的双特异性T细胞衔接器BI 836909,体外实验显示其可选择性裂解BCMA阳性骨髓瘤细胞、激活T细胞并释放细胞因子,且不受骨髓基质细胞、可溶性BCMA或APRIL影响;小鼠异种移植和食蟹猴研究中BI 836909可清除BCMA阳性浆细胞并延长生存。

要点

  • BI 836909可选择性裂解BCMA阳性骨髓瘤细胞,对BCMA阴性细胞无影响。
  • BI 836909的活性不受骨髓基质细胞、可溶性BCMA或APRIL存在的影响。
  • 小鼠异种移植和食蟹猴研究中BI 836909可清除BCMA阳性浆细胞并延长生存。

核心结论

  • BI 836909是一种高效、可选择性地清除BCMA阳性多发性骨髓瘤细胞的免疫治疗新方法。

研究设计与样本

  • 研究开发了靶向BCMA和CD3ɛ的双特异性T细胞衔接器BI 836909,并在体外、离体患者样本、小鼠异种移植模型和食蟹猴中研究其对多发性骨髓瘤的治疗作用。

主要发现

  • BI 836909诱导BCMA阳性多发性骨髓瘤细胞选择性裂解、T细胞活化、细胞因子释放和T细胞增殖,而BCMA阴性细胞未受影响。
  • BI 836909的活性不受骨髓基质细胞、可溶性BCMA或增殖诱导配体(APRIL)存在的影响。
  • 在离体实验中,BI 836909在新诊断和复发/难治患者样本中均诱导有效的自体多发性骨髓瘤细胞裂解。
  • 在小鼠异种移植研究中,BI 836909在皮下NCI-H929异种移植模型中诱导肿瘤细胞耗竭,并在原位L-363异种移植模型中延长生存。
  • 在食蟹猴研究中,给予BI 836909导致骨髓中BCMA阳性浆细胞耗竭。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA-positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2016. PMID: 28025583. doi:10.1038/leu.2016.388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。